{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:54:43Z","timestamp":1772139283272,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.vaccine.2008.01.043","type":"journal-article","created":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T14:34:44Z","timestamp":1202999684000},"page":"1893-1901","source":"Crossref","is-referenced-by-count":42,"title":["A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine"],"prefix":"10.1016","volume":"26","author":[{"given":"Xueju","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musheng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2008.01.043_bib1","unstructured":"WHO Expert Consultation on Rabies. First report. World Health Organization, Geneva, 1992 (WHO Technical Report Series; 931)."},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1201-9712(03)90046-4","article-title":"Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies","volume":"7","author":"Hemachudha","year":"2003","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib3","first-page":"7","article-title":"Rabies heads fatal disease list again","volume":"4","author":"Barrett","year":"2006","journal-title":"Vet Newslett"},{"issue":"12","key":"10.1016\/j.vaccine.2008.01.043_bib4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3201\/eid1112.050271","article-title":"Pivotal role of dogs in rabies transmission, China","volume":"11","author":"Tang","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2008.01.043_bib5","unstructured":"Centers for Disease Control and Prevention: Human rabies prevention\u2014United States, 1999: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-1):p. 1\u201317."},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib6","first-page":"39","article-title":"Post-exposure prophylaxis for rabies","volume":"7","author":"Shayam","year":"2006","journal-title":"JIACM"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/AEM.27.3.553-561.1974","article-title":"Antibody response to a human diploid cell rabies vaccine","volume":"27","author":"Cabasso","year":"1974","journal-title":"Appl Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2008.01.043_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/infdis\/150.5.785","article-title":"Rapidity of booster response to rabies vaccine produced in cell culture","volume":"50","author":"Berlin","year":"1984","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2008.01.043_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2105\/AJPH.80.4.476","article-title":"Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination","volume":"80","author":"Berlin","year":"1990","journal-title":"Am J Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2008.01.043_bib10","first-page":"133","article-title":"Influence of aluminum adjuvant to experimental rabies vaccine","volume":"13","author":"Lin","year":"1999","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"issue":"8","key":"10.1016\/j.vaccine.2008.01.043_bib11","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/IAI.67.8.3719-3726.1999","article-title":"Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major","volume":"67","author":"Stacey","year":"1999","journal-title":"Infect Immun"},{"issue":"14","key":"10.1016\/j.vaccine.2008.01.043_bib12","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1128\/JVI.75.14.6482-6491.2001","article-title":"CpG oligodeoxynucleotides with hepatitis B surface antigen for vaccination in HBsAg-transgenic mice","volume":"75","author":"Malanch\u00e8re-Br\u00e8s","year":"2001","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/IAI.74.1.528-536.2006","article-title":"CpG-Oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils","volume":"74","author":"Ivory","year":"2006","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1196\/annals.1348.030","article-title":"CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine","volume":"1082","author":"Klinman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2008.01.043_bib15","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1189\/jlb.0604330","article-title":"Orally administered OVA\/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice","volume":"77","author":"Alignani","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2008.01.043_bib16","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","article-title":"Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine","volume":"22","author":"Cooper","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2008.01.043_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J Exp Med"},{"issue":"6522","key":"10.1016\/j.vaccine.2008.01.043_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2008.01.043_bib19","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.4049\/jimmunol.160.12.5898","article-title":"CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry","volume":"160","author":"Yi","year":"1998","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.01.043_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2008.01.043_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ni941","article-title":"CpG directly induces T bet expression and inhibits IgG1 and IgE switching in B cells","volume":"4","author":"Liu","year":"2003","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2008.01.043_bib22","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.4049\/jimmunol.173.7.4479","article-title":"CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10","volume":"173","author":"He","year":"2004","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2008.01.043_bib23","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1073\/pnas.96.16.9305","article-title":"CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells","volume":"96","author":"Hartmann","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2008.01.043_bib24","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO;2-F","article-title":"CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells","volume":"32","author":"Gursel","year":"2002","journal-title":"Eur J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2008.01.043_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14760584.5.3.365","article-title":"CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine","volume":"5","author":"Klinman","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1006\/cimm.2000.1635","article-title":"Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides","volume":"201","author":"Mannon","year":"2000","journal-title":"Cell immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib28","first-page":"125","article-title":"Comparison of three serological tests for titration of rabies antibodies in immunized individuals","volume":"2","author":"Simani","year":"1999","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.vaccine.2008.01.043_bib29","first-page":"137","article-title":"Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines","volume":"86","author":"Rooijakkers","year":"1996","journal-title":"Dev Biol Stand"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib30","first-page":"493","article-title":"A simple method of estimating fifity percent end-points","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1513\/pats.200701-021AW","article-title":"Antiinfective applications of toll-like receptor 9 agonists","volume":"4","author":"Krieg","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.vaccine.2008.01.043_bib32","first-page":"687","article-title":"Activation of mouse complement by different classes of mouse antibody","volume":"38","author":"Klaus","year":"1979","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","article-title":"Fc\u03b3 receptors: old friends and new family members","volume":"24","author":"Nimmerjahn","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.vaccine.2008.01.043_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.161.1.1","article-title":"Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies","volume":"161","author":"Kipps","year":"1985","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2008.01.043_bib35","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.4049\/jimmunol.178.4.2415","article-title":"TLR9 signaling in B cells determines class switch recombination to IgG2a","volume":"178","author":"Jegerlehner","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2008.01.043_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/intimm\/12.2.223","article-title":"IFN-gamma-independent IgG2a production in mice infected with viruses and parasites","volume":"12","author":"Markine-Goriaynoff","year":"2000","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2008.01.043_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.vaccine.2008.01.043_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2249.2000.01211.x","article-title":"Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"120","author":"Furukawa","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V100.3.813","article-title":"Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo","volume":"100","author":"VandenDriessche","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.vaccine.2008.01.043_bib40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF00812260","article-title":"Thl\/Th2 balance in infection","volume":"21","author":"Infante-Duarte","year":"1999","journal-title":"Springer Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.vaccine.2008.01.043_bib41","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.4049\/jimmunol.160.8.3627","article-title":"CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis","volume":"160","author":"Zimmermann","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2008.01.043_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2460\/ajvr.2003.64.491","article-title":"Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice","volume":"64","author":"Wunderli","year":"2003","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2008.01.043_bib43","unstructured":"WHO. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Tech Rep Ser No. 840 (Annex 5) 1994."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T13:58:05Z","timestamp":1684245485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0264410X08001023"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.01.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}